Key Takeaways
- • Sydney-based Airtree, alongside Investible and Side Stage Ventures, co-invested in a $US7.4 million ($10.5 million AUD) funding round for New Zealand space-tech start-up Outlier Space, which is developing orbital manufacturing platforms for pharmaceutical production.
- • Outlier Space aims to leverage microgravity environments to manufacture drugs and materials that cannot be produced on Earth, with a test launch targeted within two years; the company will build reusable "factories" rather than manufacture products directly.
- • Microgravity manufacturing eliminates gravitational distortion that on Earth causes protein crystals to grow asymmetrically, metal alloys to separate prematurely, and human tissue to collapse under its own weight—enabling production of purer drug compounds and next-generation semiconductor materials.
- • The funding round was led by New Zealand venture capital firm GD1, with additional backing from Nova Threshold, Icehouse Ventures, and angel investor Brian Cartmell; the engineering team draws talent from both Australia and New Zealand.
- • Initial target applications span cancer treatments, Alzheimer's drug discovery, and semiconductor manufacturing, representing a significant commercial opportunity as pharmaceutical and chipmaking companies seek access to microgravity production capabilities.
Summary
Outlier Space, an Auckland-based space-technology start-up, has secured $US7.4 million in Series A funding to develop orbital manufacturing platforms designed to produce pharmaceuticals and advanced materials in microgravity environments. The round, announced on 30 July 2026, was led by New Zealand venture capital firm GD1 and backed by a syndicate of Australian and New Zealand investors, including Sydney-based Airtree—one of Australia's largest venture capital funds—alongside Investible and Side Stage Ventures. Additional investors included Nova Threshold, Icehouse Ventures, and angel investor Brian Cartmell.
The fundamental premise underlying Outlier Space's business model addresses a physics problem: gravity fundamentally distorts drug manufacturing and material production on Earth. Under normal gravitational conditions, heavy ingredients sink while lighter ones rise, convective heating stirs mixtures during crystallization, and protein crystals grow asymmetrically. Metal alloys separate before solidifying, and human tissue structures collapse under their own weight. By removing gravitational influence, molecular and surface forces become the dominant factors shaping molecular behavior, enabling the production of purer protein crystals, more uniform drug compounds, and materials that cannot be manufactured on Earth under any circumstances.
Outlier Space's business model does not involve manufacturing pharmaceuticals directly. Instead, the company is building reusable orbital "factories"—essentially specialized manufacturing platforms that will be deployed into orbit, allowing pharmaceutical and semiconductor companies to conduct production runs in microgravity and return products to Earth. Founder and Chief Executive Jamie France noted that "microgravity is an environment where gravity no longer dominates, allowing molecular and surface forces to shape behaviour that is normally hidden on Earth."
The immediate target markets span pharmaceutical development, particularly cancer treatments and Alzheimer's drug discovery, as well as next-generation semiconductor manufacturing. The company plans to conduct an initial test launch within two years. The engineering team is composed of specialists from both Australia and New Zealand, reflecting the cross-Tasman collaboration underpinning the venture. This funding represents growing institutional investor conviction that space-based manufacturing represents a viable commercial opportunity as terrestrial pharmaceutical and technology manufacturers encounter fundamental physical constraints.
The fundamental premise underlying Outlier Space's business model addresses a physics problem: gravity fundamentally distorts drug manufacturing and material production on Earth. Under normal gravitational conditions, heavy ingredients sink while lighter ones rise, convective heating stirs mixtures during crystallization, and protein crystals grow asymmetrically. Metal alloys separate before solidifying, and human tissue structures collapse under their own weight. By removing gravitational influence, molecular and surface forces become the dominant factors shaping molecular behavior, enabling the production of purer protein crystals, more uniform drug compounds, and materials that cannot be manufactured on Earth under any circumstances.
Outlier Space's business model does not involve manufacturing pharmaceuticals directly. Instead, the company is building reusable orbital "factories"—essentially specialized manufacturing platforms that will be deployed into orbit, allowing pharmaceutical and semiconductor companies to conduct production runs in microgravity and return products to Earth. Founder and Chief Executive Jamie France noted that "microgravity is an environment where gravity no longer dominates, allowing molecular and surface forces to shape behaviour that is normally hidden on Earth."
The immediate target markets span pharmaceutical development, particularly cancer treatments and Alzheimer's drug discovery, as well as next-generation semiconductor manufacturing. The company plans to conduct an initial test launch within two years. The engineering team is composed of specialists from both Australia and New Zealand, reflecting the cross-Tasman collaboration underpinning the venture. This funding represents growing institutional investor conviction that space-based manufacturing represents a viable commercial opportunity as terrestrial pharmaceutical and technology manufacturers encounter fundamental physical constraints.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.